论文部分内容阅读
目的研究比较非霍奇金淋巴瘤应用吡柔比星为主或多柔比星为主化疗的效果和安全性。方法回顾分析2009年2月-2012年2月我科收治的非霍奇金淋巴瘤应用吡柔比星化疗的30例患者(观察组)和应用多柔比星化疗的30例患者(对照组)的临床资料,比较两组患者的总缓解率和不良反应发生率。结果观察组总缓解率为86.7%,高于对照组的63.3%,组间差异有统计学意义(P<0.05);两组在白细胞下降、肝功能改变、血小板减少的不良反应比较无统计学差异(P>0.05),在脱发、心脏毒性的不良反应比较具有统计学差异(P<0.05)。结论非霍奇金淋巴瘤化疗应用吡柔比星较应用多柔比星近期缓解率高、部分不良反应的发生率低、使用安全性高,可推广使用。
Objective To compare the efficacy and safety of pirarubicin-based or doxorubicin-based chemotherapy in non-Hodgkin’s lymphoma. Methods A retrospective analysis of 30 patients (observation group) and 30 patients (control group) treated with pirarubicin in non-Hodgkin’s lymphoma treated in our department from February 2009 to February 2012 was performed. ) Clinical data, the two groups of patients with total remission rate and adverse reaction rate. Results The total remission rate in observation group was 86.7%, which was higher than that in control group (63.3%). There was significant difference between two groups (P <0.05). There was no statistical difference between the two groups in the leukopenia, liver function and thrombocytopenia (P> 0.05). There was significant difference in adverse reaction of cardiotoxicity in alopecia (P <0.05). Conclusion Non-Hodgkin’s lymphoma chemotherapy with pirarubicin compared with the application of doxorubicin recent high remission rate, the incidence of some adverse reactions, the use of high safety, and can be extended to use.